Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPN | P05981 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477332 | 1.00 | ELANE (0.78) | ELANECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL5755928 | 0.88 | ELANE (1.00) | ELANECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL5479466 | 0.81 | ELANE (0.78) | ELANECYP3A4CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL5755929 | 0.74 | ELANE (0.55) | ELANECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL14041067 | 0.69 | ELANE (0.71) | ELANECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL8344218 | 0.69 | MAPT (0.69) | ELANECYP3A4CYP2C9L3MBTL1SMN1; SMN2 | |
| SCHEMBL10656803 | 0.67 | CACNA1F (0.53) | CYP3A4CYP2C9MEN1KMT2AMAPT | |
| SCHEMBL9496402 | 0.67 | HPN (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8883552 | 0.66 | CACNA1F (0.65) | CYP3A4CYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL30296731 | 0.66 | CACNA1F (0.65) | CYP3A4CYP2C9MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199136-B2 | 1,4-dihydro-1,4-diphenylpyridine derivatives | BAYER HEALTHCARE AG (DE) | 2007-04-03 | — | — | US | disclosed |
| EP-1458682-B1 | 1,4-DIHYDRO-1,4-DIPHENYLPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | BAYER HEALTHCARE AG | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | SERPINB1, ELANE, MPO | ELANE 2/4885CYP3A4 1315/4885CYP2C9 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.